ATLAS Biolabs and Ingenuity® Systems Sign Collaboration Agreement
News Jun 20, 2012
ATLAS Biolabs and Ingenuity® Systems have signed a collaboration agreement that gives customers of ATLAS Biolabs the option to analyze and interpret their study data using Ingenuity solutions.
Ingenuity Variant Analysis will be used to identify causal variants from the output of whole genome and exome sequencing experiments and iReport will be used for the biological interpretation of RNA-Seq and other gene expression data.
Both solutions leverage the Ingenuity Knowledge Base, a repository of biological interactions and functional annotations created from millions of individually modelled relationships between proteins, genes, complexes, cells, tissues, metabolites, drugs, and diseases.
By offering the Ingenuity products, ATLAS Biolabs supports the complete workflow from project design to scientific analysis, providing its customers with high quality laboratory and bioinformatic services.
“The Ingenuity products facilitate and accelerate the bioinformatics support we provide to our customers. They allow us and our customer to interactively manoeuvre through the data and shed light on it from multiple biological perspectives, to understand the biological meaning.” explains Dr. Karsten R. Heidtke, Head of Bioinformatics at ATLAS Biolabs.
“We are very pleased to partner with ATLAS Biolabs in Europe to offer a complete “sample to insight” solution to ATLAS Biolabs’ customers combining ATLAS Biolabs’ lab services with Ingenuity’s analysis and biological interpretation solution,” stated Sean Scott, Sr. Vice President, Global Commercial Operations, Ingenuity Systems.
Scott continued, “By providing Ingenuity iReport and Ingenuity Variant Analysis, ATLAS Biolabs can support researchers working with RNA-Seq and DNA resequencing data, so that they can quickly and reliably understand the underlying biology of their experiments.”
CRISPR Reveals New Targets for Promising Cancer DrugsNews
Novel screening method identifies new drug targets that could potentially enhance the effectiveness of PD-1 checkpoint inhibitors, a promising new class of cancer immunotherapy.READ MORE
Potential Barcode Identified for a Form of Alcoholic Liver DiseaseNews
NIAAA-supported researchers have discovered that extracellular vesicles released by liver cells in a mouse model of alcoholic steatohepatitis contain a miRNA signature detectable in the blood.READ MORE
New Algorithms Help Extract 3-D Biological Structure from Limited DataNews
CAMERA researchers capitalize on their Multi-Tiered Iterative Phasing approach to determine molecular structure of proteins and viruses from X-ray free electron laser data.READ MORE
Comments | 0 ADD COMMENT
EMBL Course: Next Generation Sequencing: RNA Sequencing Library Preparation
Apr 23 - Apr 27, 2018
EMBO Practical Course: Microbial Metagenomics: A 360º Approach
Apr 23 - Apr 30, 2018
EMBL Course: Next Generation Sequencing: Whole Genome Sequencing Library Preparation
Apr 16 - Apr 20, 2018
EMBL Course: Introduction to Next Generation Sequencing
Apr 09 - Apr 12, 2018